CoChat

Identification and Analysis of In Vivo VEGF Downstream Markers Link VEGF Pathway Activity with Efficacy of Anti-VEGF Therapies

Open access
Brauer, Matthew J., Zhuang, Guanglei, Schmidt, Maike, Yao, Jenny, Wu, Xiumin, Kaminker, Joshua S., Jurinka, Stefanie S., Kolumam, Ganesh, Chung, Alicia S., Jubb, Adrian, Modrusan, Zora, Ozawa, Tomoko, James, C. David, Phillips, Heidi, Haley, Benjamin, Tam, Rachel N.W., Clermont, Anne C., Cheng, Jason H., Yang, Sherry X., Swain, Sandra M., Chen, Daniel, Scherer, Stefan J., Koeppen, Hartmut, Yeh, Ru-Fang, Yue, Peng, Stephan, Jean-Philippe, Hegde, Priti, Ferrara, Napoleone, Singh, Mallika, Bais, Carlos · 2013 · Clinical Cancer Research
Cited by 61

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Purpose: The aim of this study was to identify conserved pharmacodynamic and potential predictive biomarkers of response to anti-VEGF therapy using gene expression profiling in preclinical tumor models and in patients. Experimental Design: Surrogate markers of VEGF inhibition [VEGF-dependent genes or VEGF-dependent vasculature (VDV)] were identified by profiling gene expression changes induced in response to VEGF blockade in preclinical tumor models and in human biopsies from patients treated with anti-VEGF monoclonal antibodies. The potential value of VDV genes as candidate predictive biomarkers was tested by correlating high or low VDV gene expression levels in pretreatment clinical samples with the subsequent clinical efficacy of bevacizumab (anti-VEGF)-containing therapy. Results: We show that VDV genes, including direct and more distal VEGF downstream endothelial targets, enable detection of VEGF signaling inhibition in mouse tumor models and human tumor biopsies. Retrospective analyses of clinical trial data indicate that patients with higher VDV expression in pretreatment tumor samples exhibited improved clinical outcome when treated with bevacizumab-containing therapies. Conclusions: In this work, we identified surrogate markers (VDV genes) for in vivo VEGF signaling in tumors and showed clinical data supporting a correlation between pretreatment VEGF bioactivity and the subsequent efficacy of anti-VEGF therapy. We propose that VDV genes are candidate biomarkers with the potential to aid the selection of novel indications as well as patients likely to respond to anti-VEGF therapy. The data presented here define a diagnostic biomarker hypothesis based on translational research that warrants further evaluation in additional retrospective and prospective trials. Clin Cancer Res; 19(13); 3681–92. ©2013 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-12-3635

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 61

Metadata

Authors
Brauer, M. J., Zhuang, G., Schmidt, M., Yao, J., Wu, X., Kaminker, J. S., Jurinka, S. S., Kolumam, G., Chung, A. S., Jubb, A., Modrusan, Z., Ozawa, T., James, C. D., Phillips, H., Haley, B., Tam, R. N. W., Clermont, A. C., Cheng, J. H., Yang, S. X., Swain, S. M., Chen, D., Scherer, S. J., Koeppen, H., Yeh, R.-F., Yue, P., Stephan, J.-P., Hegde, P., Ferrara, N., Singh, M., & Bais, C.
Venue
Clinical Cancer Research
Published
2013-06-30
Volume
19
Issue
13
Pages
3681-3692
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2109154357
Cited by
61
References
9
FWCI
3.09
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Identification and Analysis of In Vivo VEGF Downstream Markers Link VEGF Pathway Activity with Efficacy of Anti-VEGF Therapies. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-12-3635
The paper
Brauer, M. J., Zhuang, G., Schmidt, M., Yao, J., Wu, X., Kaminker, J. S., Jurinka, S. S., Kolumam, G., Chung, A. S., Jubb, A., Modrusan, Z., Ozawa, T., James, C. D., Phillips, H., Haley, B., Tam, R. N. W., Clermont, A. C., Cheng, J. H., Yang, S. X., . . . Bais, C. (2013). Identification and Analysis of In Vivo VEGF Downstream Markers Link VEGF Pathway Activity with Efficacy of Anti-VEGF Therapies. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-12-3635

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.